Design, synthesis, and biological evaluation of 14-heteroaromatic- substituted naltrexone derivatives: Pharmacological profile switch from Mu opioid receptor selectivity to Mu/Kappa opioid receptor dual selectivity

Journal of Medicinal Chemistry

Volumn 56, Issue 22, 2013, Pages 9156-9169

  Yuan, Yunyun ^a   Zaidi, Saheem A ^a   Elbegdorj, Orgil ^a   Aschenbach, Lindsey C K ^a   Li, Guo ^a   Stevens, David L ^a   Scoggins, Krista L ^a   Dewey, William L ^a   Selley, Dana E ^a   Zhang, Yan ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA N(BENZAMIDO)MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA N[(2' PYRIDYL)CARBOXAMIDO]MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA N[(2' QUINOLYL)CARBOXAMIDO]MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA N[(3' ISOQUINOLYL)CARBOXAMIDO]MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA N[(3' PYRIDYL)CARBOXAMIDO]MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA N[(3' QUINOLYL)CARBOXAMIDO]MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA N[(4' PYRIDYL)CARBOXAMIDO]MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA N[2' (PYRIDIN 2'' YL)ACETAMIDO]MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA N[2' [(PYRIDIN 2'' YL)CARBOXAMIDO]ACETAMIDO}MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA N[3' (PYRIDIN 2'' YL)PROPANAMIDO]MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA O(2 NAPHTHOYLOXY)MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA O(BENZOYLOXY)MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA O(ISOQUINOLYL 3' CARBOXY)MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA O(PYRIDYL 2' CARBOXY)MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA O(PYRIDYL 3' CARBOXY)MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA O(PYRIDYL 4' CARBOXY)MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA O(QUINOLYL 2' CARBOXY)MORPHINAN 6 ONE; 17 CYCLOPROPYLMETHYL 4,5 ALPHA EPOXY 3 HYDROXY 14 BETA O(QUINOLYL 3' CARBOXY)MORPHINAN 6 ONE; KAPPA OPIATE RECEPTOR; LIGAND; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NALTREXONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ANTAGONISM; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; MORPHINE ADDICTION; MOUSE; NONHUMAN; PARTIAL AGONISM; SUBSTITUTION REACTION; TAIL FLICK TEST; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; CHEMISTRY TECHNIQUES, SYNTHETIC; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; MALE; MICE; MODELS, MOLECULAR; NALTREXONE; PROTEIN CONFORMATION; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SUBSTRATE SPECIFICITY;

EID: 84889247553     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4012214     Document Type: Article

References (58)

1. Yaksh, T. L.; Wallace, M. S. Opioids, analgesia, and pain management. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12 th ed.; Brunton, L. L., Chabner, B. A., Knollman, B. C., Eds.; McGraw-Hill Medical: New York, 2011.
2. World Drug Report 2012; Report from the United Nations Office on Drugs and Crime: New York, June, 2012; http://www.unodc.org/documents/data-and- analysis/WDR2012/WDR-2012-web-small.pdf.
3. Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. J. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog J. Pharmacol. Exp. Ther. 1976, 197, 517-532
4. Lord, J. A. H.; Waterfield, A. A.; Hughes, J.; Kosterlitz, H. W. Endogenous opioid peptides: Multiple agonists and receptors Nature 1977, 267, 495-499 (Pubitemid 8098466)
5. Davis, M. P.; Pasternak, G. W. Opioid receptors and opioid pharmacodynamics. In Opioids in Cancer Pain, 2 nd ed.; Davis, M. P.; Glare, P. A.; Hardy, J. R.; Quigley, C., Eds.; Oxford University Press: New York, 2009.
6. Bart, G. Maintenance medication for opiate addiction: The foundation of recovery J. Addict. Dis. 2012, 31, 207-225
7. Veilleux, J. C.; Colvin, P. J.; Anderson, J.; York, C.; Heinz, A. J. A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction Clin. Psychol. Rev. 2010, 30, 155-166
8. Stotts, A. L.; Dodrill, C. L.; Kosten, T. R. Opioid dependence treatment: Options in pharmacotherapy Expert Opin. Pharmacother. 2009, 10, 1727-1740
9. Isbell, H.; Vogel, V. H. The addiction liability of methadone (amidone, dolophine, 10820) and its use in the treatment of the morphine abstinence syndrome Am. J. Psychiatry 1949, 105, 909-914
10. Walsh, S. L.; Preston, K. L.; Stitzer, M. L.; Cone, E. J.; Bigelow, G. E. Clinical pharmacology of buprenorphine: Ceiling effects at high doses Clin. Pharmacol. Ther. 1994, 55, 569-580 (Pubitemid 24192243)
11. O'Brien, C. P.; Greenstein, R. A.; Mintz, J.; Woody, G. E. Clinical experience with naltrexone Am. J. Drug Alcohol Abuse 1975, 2, 365-377
12. Hollister, L. E.; Schwin, R. L.; Kasper, P. Naltrexone treatment of opiate-dependent persons Drug Alcohol Depend. 1977, 2, 203-209
13. Judson, B. A.; Carney, T. M.; Goldstein, A. Naltrexone treatment of heroin addiction: Efficacy and safety in a double-blind dosage comparison Drug Alcohol Depend. 1981, 7, 325-346 (Pubitemid 11049556)
14. Minozzi, S.; Amato, L.; Vecchi, S.; Davoli, M.; Kirchmayer, U.; Verster, A. Oral naltrexone maintenance treatment for opioid dependence Cochrane Database Syst. Rev. 2011, CD001333
15. Comer, S. D.; Sullivan, M. A.; Yu, E.; Rothenberg, J. L.; Kleber, H. D.; Kampman, K.; Dackis, C.; O'Brien, C. P. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial Arch. Gen. Psychiatry 2006, 63, 210-218 (Pubitemid 43213883)
16. Krupitsky, E.; Nunes, E. V.; Ling, W.; Illeperuma, A.; Gastfriend, D. R.; Silverman, B. L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial Lancet 2011, 377, 1506-1513
17. Broadbear, J. H.; Sumpter, T. L.; Burke, T. F.; Husbands, S. M.; Lewis, J. W.; Woods, J. H.; Traynor, J. R. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: Comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine J. Pharmacol. Exp. Ther. 2000, 294, 933-940 (Pubitemid 30666843)
18. Ward, S. J.; Portoghese, P. S.; Takemori, A. E. Pharmacological profiles of β-funaltrexamine (β-FNA) and β-chlornaltrexamine (β-CNA) on the mouse vas deferens preparation Eur. J. Pharmacol. 1982, 80, 377-384 (Pubitemid 12032168)
19. Ward, S. J.; Portoghese, P. S.; Takemori, A. E. Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine J. Pharmacol. Exp. Ther. 1982, 220, 494-498 (Pubitemid 12152158)
20. Takemori, A. E.; Larson, D. L.; Portoghese, P. S. The irreversible antagonistic properties of the fumaramate methyl ester derivative of naltrexone Eur. J. Pharmacol. 1981, 70, 445-451 (Pubitemid 11152779)
21. Schmidhammer, H.; Burkard, W. P.; Eggstein-Aeppli, L.; Smith, C. F. C. Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(Cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective μ opioid receptor antagonist J. Med. Chem. 1989, 32, 418-421 (Pubitemid 19061887)
22. Spetea, M.; Schuellner, F.; Moisa, R. C.; Berzetei-Gurske, I. P.; Schraml, B.; Doerfler, C.; Aceto, M. D.; Harris, L. S.; Coop, A.; Schmidhammer, H. Synthesis and biological evaluation of 14-Alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the μ opioid receptor antagonist cyprodime J. Med. Chem. 2004, 47, 3242-3247 (Pubitemid 38702716)
23. Sally, E. J.; Xu, H.; Dersch, C. M.; Hsin, L. W.; Chang, L. T.; Prisinzano, T. E.; Simpson, D. S.; Giuvelis, D.; Rice, K. C.; Jacobson, A. E.; Cheng, K.; Bilsky, E. J.; Rothman, R. B. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor Synapse 2010, 64, 280-288
24. Grimwood, S.; Lu, Y.; Schmidt, A. W.; Vanase-Frawley, M. A.; Sawant-Basak, A.; Miller, E.; McLean, S.; Freeman, J.; Wong, S.; McLaughlin, J. P.; Verhoest, P. R. Pharmacological characterization of 2-methyl-N-((2′- (pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors J. Pharmacol. Exp. Ther. 2011, 339, 555-566
25. Dolle, R. E.; Michaut, M.; Martinez-Teipel, B.; Seida, P. R.; Ajello, C. W.; Muller, A. L.; DeHaven, R. N.; Carroll, P. J. Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208 Bioorg. Med. Chem. Lett. 2009, 19, 3647-3650
26. Butelman, E. R.; Yuferov, V.; Kreek, M. J. κ-Opioid receptor/dynorphin system: Genetic and pharmacotherapeutic implications for addiction Trends Neurosci. 2012, 35, 587-596
27. McLaughlin, J. P.; Marton-Popovici, M.; Chavkin, C. κ Opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses J. Neurosci. 2003, 23, 5674-5683 (Pubitemid 36807845)
28. Redila, V. A.; Chavkin, C. Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system Psychopharmacology 2008, 200, 59-70
29. Walker, B. M.; Koob, G. F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence Neuropsychopharmacology 2008, 33, 643-652
30. Xi, Z. X.; Fuller, S. A.; Stein, E. A. Dopamine release in the nucleus accumbens during heroin selfadministration is modulated by kappa opioid receptors: an in vivo fast-cyclic voltammetry study J. Pharmacol. Exp. Ther. 1998, 284, 151-161 (Pubitemid 28109541)
31. Tsuji, M.; Takeda, H.; Matsumiya, T.; Nagase, H.; Narita, M.; Suzuki, T. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice Life Sci. 2001, 68, 1717-1725 (Pubitemid 32245620)
32. Shippenberg, T. S.; LeFevour, A.; Thompson, A. C. Sensitization to the conditioned rewarding effects of morphine and cocaine: Differential effects of the kappa-opioid receptor agonist U69593 Eur. J. Pharmacol. 1998, 345, 27-34 (Pubitemid 28179466)
33. Spanagel, R.; Almeida, O. F.; Bartl, C.; Shippenberg, T. S. Endogenous kappa-opioid systems in opiate withdrawal: Role in aversion and accompanying changes in mesolimbic dopamine release Psychopharmacology 1994, 115, 121-127 (Pubitemid 24207771)
34. Simonin, F.; Valverde, O.; Smadja, C.; Slowe, S.; Kitchen, I.; Dierich, A.; Le Meur, M.; Roques, B. P.; Maldonado, R.; Kieffer, B. L. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50, 488H and attenuates morphine withdrawal EMBO J. 1998, 17, 886-897 (Pubitemid 28077643)
35. Kreek, M. J.; Levran, O.; Reed, B.; Schlussman, S. D.; Zhou, Y.; Butelman, E. R. Opiate addiction and cocaine addiction: Underlying molecular neurobiology and genetics J. Clin. Invest. 2012, 122, 3387-3393
36. Wee, S.; Koob, G. F. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse Psychopharmacology 2010, 210, 121-135
37. Bruchas, M. R.; Land, B. B.; Chavkin, C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors Brain Res. 2010, 1314, 44-55
38. Li, G.; Aschenbach, L. C.; Chen, J.; Cassidy, M. P.; Stevens, D. L.; Gabra, B. H.; Selley, D. E.; Dewey, W. L.; Westkaemper, R. B.; Zhang, Y. Design, synthesis, and biological evaluation of 6 α-and 6 β-N -heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective antagonists J. Med. Chem. 2009, 52, 1416-1427
39. Yuan, Y.; Li, G.; He, H.; Stevens, D. L.; Kozak, P.; Scoggins, K. L.; Mitra, P.; Gerk, P. M.; Selley, D. E.; Dewey, W. L.; Zhang, Y. Characterization of 6 α-and 6 β -N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists ACS Chem. Neurosci. 2011, 2, 346-351
40. Li, G.; Aschenbach, L. C. K.; He, H.; Selley, D. E.; Zhang, Y. 14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: Design, synthesis, and biological studies Bioorg. Med. Chem. Lett. 2009, 19, 1825-1829
41. Kourist, R.; Domínguez de María, P.; Bornscheuer, U. T. Enzymatic synthesis of optically active tertiary alcohols: Expanding the biocatalysis toolbox ChemBioChem. 2008, 9, 491-498
42. Pogorevc, M.; Faber, K. Biocatalytic resolution of sterically hindered alcohols, carboxylic acids and esters containing fully substituted chiral centers by hydrolytic enzymes J. Mol. Catal. B: Enzym. 2000, 10, 357-376 (Pubitemid 30483990)
43. Zhang, Y.; Elbegdorj, O.; Yuan, Y.; Beletskaya, I. O.; Selley, D. E. Opioid receptor selectivity profile change via isosterism for 14-O-substitued naltrexone derivatives Bioorg. Med. Chem. Lett. 2013, 23, 3719-3722
44. Yuan, Y.; Elbegdorj, O.; Chen, J.; Akubathini, S. K.; Zhang, F.; Stevens, D. L.; Beletskaya, I. O.; Scoggins, K. L.; Zhang, Z.; Gerk, P. M.; Selley, D. E.; Akbarali, H. I.; Dewey, W. L.; Zhang, Y. Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy- 6β-[(4′-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents J. Med. Chem. 2012, 55, 10118-10129
45. Moynihan, H.; Jales, A. R.; Greedy, B. M.; Rennison, D.; Broadbear, J. H.; Purington, L.; Traynor, J. R.; Woods, J. H.; Lewis, J. W.; Husbands, S. M. 14β-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity J. Med. Chem. 2009, 52, 1553-1557
46. Yuan, Y.; Stevens, D. L.; Braithwaite, A.; Scoggins, K. L.; Bilsky, E. J.; Akbarali, H. I.; Dewey, W. L.; Zhang, Y. 6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists Bioorg. Med. Chem. Lett. 2012, 22, 4731-4734
47. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal structure of the mu opioid receptor bound to a morphinan antagonist Nature 2012, 485, 321-326
48. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human κ-opioid receptor in complex with JDTic Nature 2012, 485, 327-332
49. Granier, S.; Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Weis, W. I.; Kobilka, B. K. Structure of the δ-opioid receptor bound to naltrindole Nature 2012, 485, 400-404
50. Bera, I.; Laskar, A.; Ghoshal, N. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: A comparative study J. Mol. Model. 2011, 17, 1207-1221
51. Greiner, E.; Spetea, M.; Krassnig, R.; Schüllner, F.; Aceto, M.; Harris, L. S.; Traynor, J. R.; Woods, J. H.; Coop, A.; Schmidhammer, H. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-Substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: Extending the scope of common structure-activity relationships J. Med. Chem. 2003, 46, 1758-1763 (Pubitemid 36444228)
52. Nieland, N. P.; Moynihan, H. A.; Carrington, S.; Broadbear, J.; Woods, J. H.; Traynor, J. R.; Husbands, S. M.; Lewis, J. W. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: Effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones J. Med. Chem. 2006, 49, 5333-5338 (Pubitemid 44260227)
53. Moynihan, H.; Jales, A. R.; Greedy, B. M.; Rennison, D.; Broadbear, J. H.; Purington, L.; Traynor, J. R.; Woods, J. H.; Lewis, J. W.; Husbands, S. M. 14β-O-Cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity J. Med. Chem. 2009, 52, 1553-1557
54. Nieland, N. P.; Rennison, D.; Broadbear, J. H.; Purington, L.; Woods, J. H.; Traynor, J. R.; Lewis, J. W.; Husbands, S. M. 14β-Arylpropiolylamino- 17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists J. Med. Chem. 2009, 52, 6926-6930
55. Coderre, T. J.; Rollman, G. B. Naloxone hyperalgesia and stress-induced analgesia in rats Life Sci. 1983, 32, 2139-2146 (Pubitemid 13135558)
56. Harris, L. S.; Pierson, A. K. Some narcotic antagonists in the benzomorphan series J. Pharmacol. Exp. Ther. 1964, 143, 141-148
57. Niratisai, S. Synthesis of 14β-amino isosteric analogs of naltrindole and norbinaltorphimine: Role of 14β-amino group and its acyl substituents on delta- and kappa-selective opioid receptor antagonism. Ph.D. Thesis, University of Minnesota, 2003.
58. Calderon, S. N.; Rothman, R. B.; Porreca, F.; Flippen-Anderson, J. L.; McNutt, R. W.; Xu, H.; Smith, L. E.; Bilsky, E. J.; Davis, P.; Rice, K. C. Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A highly selective, nonpeptide delta opioid receptor agonist J. Med. Chem. 1994, 37, 2125-2128 (Pubitemid 24228438)